Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]-Elinzanetant in Healthy Males
NCT04654897Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elinzanetant in vasomotor symptoms, sponsored by Bayer. Primary endpoints: Mass Balance Recovery of Total Radioactivity: CumAe(Urine) at Day 45, Mass Balance Recovery of Total Radioactivity: Cum%Ae(Urine) at Day 45 and 4 more. Started Sep 2020; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04654897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654897.